What if we could target ageing in Parkinson’s disease?

Mickael Decressac’s lab at the Telethon Institute of Genetics and Medicine (TIGEM) aims to identify potential therapeutic targets of Parkinson’s, validate them in relevant and complementary models of the condition, and finally, design clinically relevant strategies in order to bring them to the bedside.

In 2012, he developed a viral vector-based model of Parkinson’s, which is widely used for studying the pathological mechanisms and testing protective therapies. Notably, he used this model to uncover novel mechanisms underlying the response of affected neurons to neurotrophic factors and contributed to understanding how the cellular clearance pathways are involved in the disease process. His current research is focused on understanding and modeling Parkinson’s as well as developing new therapeutic approaches using translational approaches.